Sprout announces availability of Addyi REMS training

RALEIGH, N.C. — Sprout Pharmaceuticals recently announced that pharmacists and providers can now enroll Risk Evaluaiton and Mitigation Strategy training to become certified to prescribe or dispense Addyi (filbanserin), the recently approved drug that treats hypoactive sexual desire disorder in premenopausal women. 

 

“We are committed to patient safety first and foremost, and as such, our priority is to educate prescribers and pharmacies about Addyi leading up to its availability,” Sprout CEO Cindy Whitehead said. “The millions of women who suffer from HSDD have been awaiting a treatment option for years, and we look forward to working with healthcare providers and pharmacies to provide them with education on Addyi.”

 

The REMS materials can be accessed from Addyi.com and prescriber and pharmacists have to review and complete a knowledge assessment. The program is designed to reduce the risk of syncope and hypertension that can occur when Addyi interacts with alcohol.